Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(18):1329-1331; doi:10.1093/jnci/90.18.1329
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Derrane, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Derrane, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Bisphosphonates: Lingering Questions About Their Use

In a recent article in The New England Journal of Medicine, researchers found that a member of a class of drugs known for their ability to help stop bone destruction also reduced the incidence and the number of new bony and visceral (soft tissue) metastases in breast cancer patients at high risk for distant disease.

The drug, oral clodronate, which is not yet available in the United States, is a bisphosphonate -- a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?